FIELD: medicine.
SUBSTANCE: invention concerns medicine, namely haematology, cardiology and endocrinology, and covers correction of thrombocyte intravascular activity in patients suffering from arterial hypertension with impaired glucose tolerance. It is ensured by integrated treatment including graduated static and dynamic loading, and introduction of pioglitazone in a dose 30 mg once a day in the morning and lisinopril in a dose 10 mg once a day in the morning.
EFFECT: such complex of specific medical agents and physical activity provides short-term - within 1,5 months - normalisation of thrombocyte intravascular activity that in turn reduces risk of thrombotic complications in given group of patients.
1 ex
